Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)

v3.20.4
STOCKHOLDERS' EQUITY (DEFICIT) (Tables)
 12 Months Ended
Nov. 30, 2020
Equity [Abstract]  
Schedule of assumptions used for warrants

The assumptions that the Company used to determine the grant-date fair value of warrants granted for the years ended November 30, 2020 and 2019 were as follows:

      2020   2019
  Risk free rate     0.35 – 1.57%       1.69 – 3.05%  
  Expected dividends     0 %     0 %
  Expected volatility     98.28 – 109.93%       150 – 159%  
  Expected life     3.54 – 3.77 years       4.35 – 5 years  
  Market price of the Company's common stock on date of grant   $ 0.25       $0.14 – 0.16  
  Exercise price   $ 0.25     $ 0.25  

 
Schedule of warrants activity

The following table summarizes warrant activity, which includes the incentive warrants, for the year ended November 30, 2020:

 

      Number of
Warrants		     Weighted-Average
Exercise
Price
$		  
               
Outstanding, November 30, 2018       26,041,160       0.19  
Granted       22,223,058       0.25  
Expired       (2,476,999 )     (0.16 )
Outstanding, November 30, 2019       45,787,219       0.22  
Granted       2,146,836       0.25  
Exercised       (42,076,668 )     (0.21 )
Outstanding, November 30, 2020       5,857,386       0.24  
                   
Exercisable, November 30, 2020       5,857,386       0.24  
Exercisable. November 30, 2019       45,037,219       0.22
Schedule weighted-average remaining contract

The warrants outstanding at the end of the year had weighted-average remaining contract lives as follows:

 

    2020     2019  
      (years)       (years)  
Total outstanding warrants     2.82       3.55  
Total exercisable warrants     2.82       3.50